<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Chem.</journal-id>
<journal-title>Frontiers in Chemistry</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Chem.</abbrev-journal-title>
<issn pub-type="epub">2296-2646</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1043810</article-id>
<article-id pub-id-type="doi">10.3389/fchem.2022.1043810</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Chemistry</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A novel biocompatible Eu-based coordination polymers of cytarabine anticancer drug: Preparation, luminescence properties and <italic>in vitro</italic> anticancer activity studies</article-title>
<alt-title alt-title-type="left-running-head">Zeng et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fchem.2022.1043810">10.3389/fchem.2022.1043810</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zeng</surname>
<given-names>Zhijun</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/1949169/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shen</surname>
<given-names>Huaxiang</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>Wei</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Qifeng</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Mengjie</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yan</surname>
<given-names>Xiaojun</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Hongning</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ji</surname>
<given-names>Yanhua</given-names>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
</contrib-group>
<aff id="aff">
<institution>Research Center for Differention and Development of TCM Basic Theory</institution>, <institution>Jiangxi Province Key Laboratory of TCM Etiopathogenisis</institution>, <institution>Jiangxi University of Chinese Medicine</institution>, <addr-line>Nanchang</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1706873/overview">Prateeti Chakraborty</ext-link>, Bangabasi College, India</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/883109/overview">Xicheng Liu</ext-link>, Qufu Normal University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/889591/overview">Lihua Guo</ext-link>, Qufu Normal University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Yanhua Ji, <email>553753722@qq.com</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Inorganic Chemistry, a section of the journal Frontiers in Chemistry</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>11</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>10</volume>
<elocation-id>1043810</elocation-id>
<history>
<date date-type="received">
<day>14</day>
<month>09</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>10</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Zeng, Shen, Gao, Guo, Chen, Yan, Liu and Ji.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Zeng, Shen, Gao, Guo, Chen, Yan, Liu and Ji</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>In this study, we use cytarabine anticancer drug to synthesize a new rare earth complex with Europium ion. The study work is an attempt to investigate luminescence and biological properties of the Eu-based coordination polymers of cytarabine (Eu-CP-Ara) anticancer drug which have been prepared by us. Eu-CP-Ara has luminescence properties with emission centering at about 619&#xa0;nm excited with 394&#xa0;nm. We study cytarabine and Eu-CP-Ara <italic>in vitro</italic> cytotoxicity. Cytotoxicity of Eu-CP-Ara against lung cancer cells (A549) could even be comparable to the inhibitory effect of cytarabine ligands, showing the advantage of antitumor activity. In addition, Eu-CP-Ara showed lower cytotoxicity to normal liver cells (L02). At the same, from the CLSM images, Eu-CP-Ara has successfully entered the A549 cell. Hence, Eu-CP-Ara can be used as a potential anticancer drug. Eu-CP-Ara may be an effective strategy for the tracking cytarabine against tumours and might impart better accurate treatment effect and therapeutic efficiency.</p>
</abstract>
<abstract abstract-type="graphical">
<title>Graphical Abstract</title>
<p>
<graphic xlink:href="FCHEM_fchem-2022-1043810_wc_abs.tif" position="anchor"/>
</p>
</abstract>
<kwd-group>
<kwd>Eu-based coordination polymers (Eu-CP-Ara)</kwd>
<kwd>cytarabine</kwd>
<kwd>luminescence properties</kwd>
<kwd>anticancer drug</kwd>
<kwd>cytotoxicity</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Cancer has disturbed human livelihood and health for a long time, which is one of the most serious diseases (<xref ref-type="bibr" rid="B39">Shu et al., 2021</xref>; <xref ref-type="bibr" rid="B44">Wuttke et al., 2015</xref>; <xref ref-type="bibr" rid="B49">Zhang and Zhao, 2018</xref>). Cytarabine (Ara-C) is an anticancer drug used for chemotherapeutic agent, which can treat the acute myeloblastic leukemia, individualized by abnormal proliferation of myeloid blasts in hematopoietic stem (<xref ref-type="bibr" rid="B13">Hirsch et al., 2017</xref>; <xref ref-type="bibr" rid="B25">Liu et al., 2018</xref>). Sometimes, cytarabine is also used as combination treatment drug to treat disease with other therapeutic method. For example, Low-dose cytarabine could combine exchange transfusion (ET) to treat Down syndrome without developing acute leukemia, liver failure, or other serious adverse events (<xref ref-type="bibr" rid="B31">Okamura et al., 2019</xref>). High-dose cytosine arabinoside combine autologous hematopoietic stem cell transplantation to treat mantle cell lymphoma (<xref ref-type="bibr" rid="B6">Cakar et al., 2020</xref>; <xref ref-type="bibr" rid="B30">Nato et al., 2021</xref>; <xref ref-type="bibr" rid="B33">Pola et al., 2021</xref>). Cytarabine (cytosine arabinoside 1-&#x3b2;-D-Arabinofuranosylcytosine, Ara-C) is a pyrimidine nucleoside analog, which could combine other anticancer drugs to treat solid tumors and show superbly synergistic effects against (<xref ref-type="bibr" rid="B17">Jabbour et al., 2007</xref>). For example, the combination of decitabine, idarubicin, and cytarabine chemotherapy drugs can treat acute myeloid leukemia and high-risk myelodysplastic syndrome (<xref ref-type="bibr" rid="B48">Zhang and Guo, 2019</xref>). This therapeutic method can improve survival of elderly patients and reduce early mortality (<xref ref-type="bibr" rid="B21">Kantarjian et al., 2012</xref>; <xref ref-type="bibr" rid="B48">Zhang and Guo, 2019</xref>). Cytarabine unite with sequential dosing of decitabine used in the treatment of acute myeloid leukaemia in children (<xref ref-type="bibr" rid="B22">Kearns et al., 2019</xref>). This novel therapeutic strategy is more effective than either agent alone in relapsed and refractory (<xref ref-type="bibr" rid="B24">Leonard et al., 2014</xref>; <xref ref-type="bibr" rid="B22">Kearns et al., 2019</xref>). Therefore, cytarabine anticancer drug are very important and useful in treating acute myeloid leukaemia. However, it has many severely drawbacks such as rapid plasma metabolism indicating a short half-life and low lipophilicity (<xref ref-type="bibr" rid="B25">Liu et al., 2018</xref>), which are extremely limiting clinical applications. Cytarabine has a certain inhibitory effect on acute leukemia and other cancer cells, but the anti-tumor effect of single cytarabine is limited, and its anti-tumor activity and various biological activities can be enhanced by forming complexes with metals.</p>
<p>In 1965, the American scientist Rosenberg&#x2019;s group study revealed that cisplatin had anti-tumor activity and it showed a wide range of anti-cancer biological activity. This research results has led many scientists to pay attention to Inorganic-Organic Hybrid metal complexes, especially for the anticancer drug properties and activity of metal complexes (<xref ref-type="bibr" rid="B3">Alinaghi et al., 2020</xref>; <xref ref-type="bibr" rid="B14">Holmes, 2015</xref>; <xref ref-type="bibr" rid="B32">Pettinari et al., 2020</xref>; <xref ref-type="bibr" rid="B37">Shen et al., 2020</xref>; <xref ref-type="bibr" rid="B49">Zhang and Zhao, 2018</xref>), such as new imidazolium-based palladium (II) saldach complexes as potential anticancer agents to treat cancer patients (<xref ref-type="bibr" rid="B2">Alfaifi et al., 2019</xref>). Cisplatin which has anti-cancer activity also showed nephrotoxicity and neurotoxicity in biomedicine (<xref ref-type="bibr" rid="B4">Ameri et al., 2022</xref>). Discovering low-toxicity and high-efficiency anti-cancer drugs is the focus of many researchers. The coordination polymers have a rapid development in these years. At the same time, lanthanide coordination polymers have gained great attentions in recent years. Lanthanides, yttrium, and scandium are collectively referred to as rare earth elements. It has been reported that rare earths can regulate the aquaporins of plants and prevent the damage of cell membranes by active oxygen in the body, which can increase the water content of cells and achieve the effect of promoting plant growth and drought resistance (<xref ref-type="bibr" rid="B35">Salgado et al., 2020</xref>; <xref ref-type="bibr" rid="B42">Vorob&#x2019;ev et al., 2019</xref>). Rare earths can affect the metabolism of hormones in the body, regulate the endocrine system, and increase the activity of enzymes (<xref ref-type="bibr" rid="B11">He et al., 2003</xref>; <xref ref-type="bibr" rid="B36">Schwabe et al., 2012</xref>). Because lanthanide coordination polymers not only have unique applications, but also own potential applications in biomedicine (<xref ref-type="bibr" rid="B43">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="B10">Garcia-Valdivia et al., 2020</xref>; <xref ref-type="bibr" rid="B27">Liu et al., 2020</xref>), such as antitumor, antimicrobial, anticoagulant action, antivirus, which have been researched in recent decades (<xref ref-type="bibr" rid="B26">Liu and Yang, 2009</xref>; <xref ref-type="bibr" rid="B40">Trusova et al., 2013</xref>; <xref ref-type="bibr" rid="B20">Kant and Maji, 2021</xref>). In addition, lanthanide coordination polymers have good luminescence properties. Nowadays, many coordination polymers drugs, nanoparticles and materials have been used for anticancer activity study (<xref ref-type="bibr" rid="B1">Abanades Lazaro et al., 2018</xref>; <xref ref-type="bibr" rid="B38">Shen et al., 2018</xref>; <xref ref-type="bibr" rid="B41">Usman et al., 2021</xref>). For example, Eu(III)-based coordination polymer nanoparticles were investigated to anti-oral cancer studies (<xref ref-type="bibr" rid="B49">Zhang and Zhao, 2018</xref>). There are many reports on Eu(III)-based coordination polymer used in physical aspects such as structure and fluorescence (<xref ref-type="bibr" rid="B5">Arru&#xe9; et al., 2021</xref>; <xref ref-type="bibr" rid="B15">Horniichuk et al., 2021</xref>; <xref ref-type="bibr" rid="B23">Khanagwal et al., 2021</xref>). However, Eu(III)-based coordination polymer used to anticancer drug are still fewer to report.</p>
<p>In terms of coordination polymer synthesis, there are heating reflux (<xref ref-type="bibr" rid="B8">Eftekhari far and Nasr-Esfahani, 2019</xref>), hydrothermal method (<xref ref-type="bibr" rid="B12">He et al., 2017</xref>; <xref ref-type="bibr" rid="B9">Fan et al., 2018</xref>), microwave radiation method (<xref ref-type="bibr" rid="B16">Ibarra-V&#xe1;zquez et al., 2019</xref>), ultrasonic method (<xref ref-type="bibr" rid="B34">Razmara and Poorsargol, 2019</xref>), and solvothermal method developed from hydrothermal synthesis (<xref ref-type="bibr" rid="B28">Long et al., 2019</xref>), <italic>etc.</italic> In this work, Eu-based coordination polymers of cytarabine anticancer drug have been prepared under solvothermal conditions. We used cytarabine as the ligand that is an anticancer drug, europium (III) as the ligand metal, which possess interesting luminescent properties. These luminescent properties are conducive our to observe anticancer drug situation. We synthesized the coordination polymers that the morphologies are sphere-like with the size about 100&#xa0;nm-2.5&#xa0;&#x3bc;m. To date, few papers have been reporting this synthetic method. Therefore, the sphere-like product will be discussed herein.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and methods</title>
<sec id="s2-1">
<title>Materials</title>
<p>Eu(NO<sub>3</sub>)<sub>3</sub>&#x387;6H<sub>2</sub>O (purity: 99.99%) were purchased from the city of Shanghai Aladdin Industrial Corporation (China). Cytarabine were also purchased from the city of Shanghai Macklin biochemical technology (China). All aqueous solutions were prepared using Milli-Q 10 water (resistivity&#x3e;18&#xa0;M&#x3a9;&#xa0;cm). All chemical reagents and solvents used in this work were of analytical grade and were used without further purification.</p>
</sec>
<sec id="s2-2">
<title>Instruments</title>
<p>FEI Quant 250FEG scanning electron microscopy (FEI Company, United States). ARL 3000 Desktop XRD Analyzer (Jingong Instrument (Suzhou) Co., LTD, French). ESXTAR6000 TG/DTA Thermal Difference Analyzer (Japan Seiko Electronics Nano Technology Co., LTD, Japan). Nicolet IS5 infrared spectrometer (Nicolet, United States). LEICA TCS STEDCW Ultra high-resolution microscope system (Leica Microsystems, Germany). HITACHI F-7000 Fluorescence spectrophotometer (Hitachi Scientific Instruments (Beijing) Co. LTD, Japan).</p>
</sec>
<sec id="s2-3">
<title>Preparation of Eu-based coordination polymers of cytarabine anticancer drug</title>
<p>In this work, Eu-CP of cytarabine anticancer drug micro/nanospheres were prepared for the first time. In a typical synthesis procedure, 0.3&#xa0;mmol of cytarabine anticancer drug was placed in a 20&#xa0;ml Teflon-lined stainless-steel autoclave. Then it was dissolved in 10&#xa0;ml absolute methanol under magnetic stirring. Then, 0.3&#xa0;mmol Eu<sup>3&#x2b;</sup> was added to the above solution. Finally, we used triethylamine to adjust the PH of the above solution until the PH value was about 7. The autoclave was sealed and heated at 160&#xb0;C for 6&#xa0;h. The final products were collected by centrifugation and washed several times with ethanol and distilled water. The precipitate was dried at 60&#xb0;C for 10&#xa0;h in the end.</p>
</sec>
<sec id="s2-4">
<title>Cytotoxic activities experiment <italic>in vitro</italic>
</title>
<p>The tested compounds were dissolved in sterile water and diluted to the required concentration with culture. After the required concentration of solution was configured, 0.22&#xa0;&#x3bc;m microporous membrane filter was used for filtration and sterilization. A549 cells were grown in F12 medium supplemented with 10% freshly inactivated fetal calf serum and antibiotics. L02 cells were grown in RPMI-1640 medium supplemented with 10% freshly inactivated fetal calf serum and antibiotics. The cells harvested from exponential phase (1 &#xd7; 10 <sup>5</sup>per ml) per well in 100&#xa0;&#x3bc;l of medium were seeded equivalently into a 96-well plate and then incubated for 6&#xa0;h at 37&#xb0;C and 5% CO<sub>2</sub>, then the tested compounds were added in a concentration gradient, and the final concentrations were, respectively, maintained at 96, 48, 24, 12, 3, 1.5, 0.5&#xa0;&#x3bc;g/ml. The plates were kept at 37&#xb0;C in a humidified atmosphere of 5% CO<sub>2</sub> and incubated for 48&#xa0;h, the diluent of MTT of an appropriate concentration was added to each well and the plates incubated at 37&#xb0;C and 5% CO<sub>2</sub> for 4&#xa0;h. Then suck the supernatant were added 110&#xa0;&#x3bc;l formazan solution to each well, put on a shaking table and oscillated at low speed for 10&#xa0;min to fully dissolve the crystals. The measurements of absorbance of the solutions related to the number of live cells were performed on an ELISA spectrophotometer at 450&#xa0;nm.</p>
</sec>
<sec id="s2-5">
<title>Data processing and statistical analyses</title>
<p>The results of the experimental data are expressed as mean &#xb1; standard error of mean. The differences between the two groups were analysed by <italic>t</italic>-test; the differences between multiple groups were compared by one-way analysis of variance using the software program R (<ext-link ext-link-type="uri" xlink:href="http://www.r-project.org/">http://www.r-project.org/</ext-link>). <italic>p</italic> &#x3c; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>Results and discussion</title>
<sec id="s3-1">
<title>Characterization of micro/nanoparticles</title>
<p>The SEM and TEM image with sphere-shape characterization shows that complex 1 prepared by solvothermal method has the average size around 100&#xa0;nm&#x223c;2.5&#xa0;&#x3bc;m (<xref ref-type="fig" rid="F1">Figures 1A&#x2013;E</xref>). The SEM image of developed Eu-CP-Ara revealed uniform, smooth surface, and spherical shape (<xref ref-type="fig" rid="F1">Figure 1</xref>). The amplifying TEM reveal that Eu-CP-Ara is solid spherical shape. Moreover, this product showed good dispersibility when Eu-CP-Ara was dispersed in F12 medium (<xref ref-type="fig" rid="F1">Figure 1F</xref>) gand RPMI-1640 medium (<xref ref-type="fig" rid="F1">Figures 1H,I</xref>). After 6&#xa0;days, the dispersed solution was still very stable (<xref ref-type="fig" rid="F1">Figures 1F&#x2013;I</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Surface morphology evaluation of the developed Eu-CP-Ara by SEM at different magnifications <bold>(A&#x2013;D)</bold>. TEM images of Eu-CP-Ara micro/nanosphere assembly. The scale micro/nanosphere of the inset is 100&#xa0;nm&#x223c;2.5&#xa0;&#x3bc;m <bold>(E)</bold>. Eu-CP-Ara micro/nanosphere with a concentration of 200&#xa0;&#x3bc;g&#xa0;ml<sup>&#x2212;1</sup> after 6&#xa0;days <bold>(F,H)</bold> and the above solution obtained after centrifuging at 10,000&#xa0;rpm <bold>(G,I)</bold>.</p>
</caption>
<graphic xlink:href="fchem-10-1043810-g001.tif"/>
</fig>
<p>It has been reported that different reaction time has great influence on the morphology of products (<xref ref-type="bibr" rid="B18">Ji et al., 2020</xref>). So the stability of the Eu-CP-Ara micro/nanosphere was tested in different reaction time and recorded by SEM observation. The SEM image show that Eu-CP-Ara micro/nanosphere was very stable (<xref ref-type="fig" rid="F2">Figure 2</xref>). The morphology of products did not change shape and remained spherical.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>SEM images of Eu-CP-Ara micro/nanosphere after response time for 24&#xa0;h <bold>(A,B)</bold>, 12&#xa0;h <bold>(C)</bold> and 6&#xa0;h <bold>(D)</bold>.</p>
</caption>
<graphic xlink:href="fchem-10-1043810-g002.tif"/>
</fig>
<p>XRD pattern of the Eu-CP-Ara is shown in <xref ref-type="fig" rid="F3">Figure 3A</xref>. It obviously displays that the Eu-CP-Ara is amorphous. The peak at 3,476&#xa0;cm<sup>&#x2212;1</sup> and 3438&#xa0;cm<sup>&#x2212;1</sup> are due to the antisymmetric stretching vibration and symmetric stretching vibration of amino group (<xref ref-type="fig" rid="F3">Figure 3B</xref>). The peak at 3,355&#xa0;cm<sup>&#x2212;1</sup> is show the absorption peak of oxyhydrogen stretching vibration (<xref ref-type="fig" rid="F3">Figure 3B</xref>). By comparing the infrared image of cytarabine with its complexes, the amino peak and hydroxyl peak of cytarabine at 3,476&#xa0;cm<sup>&#x2212;1</sup>, 3,438&#xa0;cm<sup>&#x2212;1</sup>, and 3,355&#xa0;cm<sup>&#x2212;1</sup> have disappeared. But it is shown in <xref ref-type="fig" rid="F3">Figure 3B</xref> that a wide peak at 3,425&#xa0;cm<sup>&#x2212;1</sup> is the stretching vibration of coordinate bond exists. The FT-IR results also confirms the formation of coordination polymer. TG and DTA curves of Eu-CP-Ara (<xref ref-type="fig" rid="F3">Figure 3C</xref>) were also detected under atmospheric conditions at 800&#xb0;C.TG analysis displays that the first mass loss in the range of 50&#x2013;200&#xb0;C is 12.0%, manifesting the loss of the physically absorbed water molecules. Two apparent decompositions between 200&#xb0;C to 570&#xb0;C and 575&#xb0;C&#x2013;665&#xb0;C of the weight loss are ascribed to the cytarabine and Eu-CP-Ara frameworks.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>
<bold>(A)</bold> XRD pattern, <bold>(B)</bold> IR spectrum and <bold>(C)</bold> TG-DTA curves of Eu-CP-Ara (Complex 1).</p>
</caption>
<graphic xlink:href="fchem-10-1043810-g003.tif"/>
</fig>
<p>
<xref ref-type="fig" rid="F4">Figure 4</xref> shows elemental mapping of Eu-CP-Ara micro/nanoparticle, it can be seen that the sphere-shape micro/nanoparticle consists of Eu, C, N, and O. The distribution of nitrogen is less (<xref ref-type="fig" rid="F5">Figure 5D</xref>). In addition, the uniform distributions of Eu (<xref ref-type="fig" rid="F5">Figure 5B</xref>), C (<xref ref-type="fig" rid="F5">Figure 5C</xref>), N (<xref ref-type="fig" rid="F5">Figure 5D</xref>), and O (<xref ref-type="fig" rid="F5">Figure 5E</xref>) in Eu-CP-Ara sphere-shaped were further evidenced by EDS images in <xref ref-type="fig" rid="F5">Figure 5</xref>. Elementary analysis shows that the percentage of europium content is 25.90%, the carbon content is 27.53%, the nitrogen content is 10.71%, and the oxygen content is 35.86%. Based on above results, the product can be proposed to be 2Eu&#xb7;3(C<sub>9</sub>H<sub>13</sub>N<sub>3</sub>O<sub>5</sub>)&#xb7;8(H<sub>2</sub>O).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>EDS diagram of Eu-CP-Ara.</p>
</caption>
<graphic xlink:href="fchem-10-1043810-g004.tif"/>
</fig>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Elemental mapping images (EDS) of Eu-CP-Ara for <bold>(A)</bold> all the elements; <bold>(B)</bold> Eu; <bold>(C)</bold> C; <bold>(D)</bold> N; <bold>(E)</bold> O.</p>
</caption>
<graphic xlink:href="fchem-10-1043810-g005.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Photoluminescence spectroscopy of micro/nanoparticles</title>
<p>The emission spectra of the Eu-CP-Ara excited with 394&#xa0;nm were shown in <xref ref-type="fig" rid="F6">Figure 6</xref>, From the emission spectrum of Eu-CP-Ara particle, these Eu-CP-Ara particles show the three peaks located in 592&#xa0;nm, 619&#xa0;nm, 699&#xa0;nm were all the typical emission of Eu<sup>3&#x2b;</sup> ions, the Eu<sup>3&#x2b;</sup> ions exhibit dominant red emission ascribed to <sup>5</sup>D<sub>0</sub>&#x2192;<sup>7</sup>F<sub>1</sub>, <sup>5</sup>D<sub>0</sub>&#x2192;<sup>7</sup>F<sub>2</sub>, <sup>5</sup>D<sub>0</sub>&#x2192;<sup>7</sup>F<sub>3</sub> transitions of Eu<sup>3&#x2b;</sup>.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Emission spectra of Eu-CP-Ara particles under 394&#xa0;nm excitation.</p>
</caption>
<graphic xlink:href="fchem-10-1043810-g006.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>Cytotoxic activity of the micro/nanoparticles</title>
<p>As shown in <xref ref-type="fig" rid="F7">Figure 7</xref>, the A549 cells uptake situation were detected by CLSM (<xref ref-type="bibr" rid="B50">Zou et al., 2017</xref>; <xref ref-type="bibr" rid="B7">Cheng et al., 2019</xref>; <xref ref-type="bibr" rid="B29">Lu et al., 2020</xref>). To understand the result of cell death in this Eu-CP-Ara, we investigated the intracellular distribution of the Eu-CP-Ara under a confocal laser scanning microscopy (CLSM) (<xref ref-type="fig" rid="F7">Figure 7</xref>). From the CLSM images, the fluorescence intensity in green color could be clearly seen in the cell. Eu-CP-Ara has successfully entered the A549 cell and was distributed throughout the cell. In order to prove this conclusion, the CLSM images was utilized to further confirm the distribution of Eu-CP-Ara at the light field image (<xref ref-type="fig" rid="F7">Figure 7A</xref>) and the results are shown in <xref ref-type="fig" rid="F7">Figure 7B</xref>. The fluorescence of Eu-CP-Ara was mostly overlapped with that of the corresponding A549 cells. The results suggested that Eu-CP-Ara tended to enter in A549 cells and had good biocompatibility (<xref ref-type="bibr" rid="B19">Ji et al., 2021</xref>; <xref ref-type="bibr" rid="B46">Zeng et al., 2019</xref>; <xref ref-type="bibr" rid="B47">Zhang et al., 2022</xref>).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>CLSM images after incubating A549 cells with Eu-CP-Ara. <bold>(A)</bold> Distribution of Eu-CP-Ara in A549 cells at the bright field image for 24&#xa0;h. <bold>(B)</bold> Distribution of Eu-CP-Ara cells at the dark field image for 6&#xa0;h after incubating A549 cells with Eu-CP-Ara.</p>
</caption>
<graphic xlink:href="fchem-10-1043810-g007.tif"/>
</fig>
<p>Cytotoxicity experiments the cytotoxicity of cytarabine with Eu-CP-Ara against A549 was investigated (<xref ref-type="fig" rid="F8">Figure 8</xref>). In addition, the cell viability of A549 and L02 were tested, respectively, in the presence of cytarabine, Eu-CP-Ara and europium nitrate hexahydrate (<xref ref-type="fig" rid="F9">Figures 9</xref>&#x2013;<xref ref-type="fig" rid="F11">11</xref>). As shown in <xref ref-type="fig" rid="F8">Figure 8</xref>, it is obvious to see that there is a large difference in the inhibition rate of cytarabine <italic>versus</italic> Eu-CP-Ara on A549 cell viability. We can easily draw a conclusion that both Cytarabine and Eu-CP-Ara have strong inhibition on this cell, and the cell inhibition rate was positively correlated with the drug concentration (<xref ref-type="bibr" rid="B45">Zeng et al., 2020</xref>). Proliferation of A549 was almost unaffected in the presence of equivalent europium nitrate hexahydrate alone. This suggests that europium ions may have a synergistic effect with cytarabine to produce a stronger toxic effect on tumor cells. And, Eu-CP Ara had lower cytotoxicity against L02 cells.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>Inhibitory rates of cytarabine and Eu-CP-Ara at different concentrations on A549 cells (0.68, 1.37, 2.73, 5.47, 10.94, 21.87, 43.74, and 87.48&#xa0;&#x3bc;g/ml).</p>
</caption>
<graphic xlink:href="fchem-10-1043810-g008.tif"/>
</fig>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>Cell viability of europium nitrate hexahydrate at different concentrations on A549 cells (0.25, 0.75, 1.5, 3, 6, 12, 24, and 48&#xa0;&#x3bc;g/ml).</p>
</caption>
<graphic xlink:href="fchem-10-1043810-g009.tif"/>
</fig>
<fig id="F10" position="float">
<label>FIGURE 10</label>
<caption>
<p>Cell viability of cytarabine and Eu-CP-Ara at different concentrations on L02 cells (0.75, 2.25, 4.5, 18, 36, 48, 60, and 72&#xa0;&#x3bc;g/ml).</p>
</caption>
<graphic xlink:href="fchem-10-1043810-g010.tif"/>
</fig>
<fig id="F11" position="float">
<label>FIGURE 11</label>
<caption>
<p>Cell viability of europium nitrate hexahydrate at different concentrations on L02 cells (0.75, 2.25, 4.5, 18, 36, 48, 60, and 72&#xa0;&#x3bc;g/ml).</p>
</caption>
<graphic xlink:href="fchem-10-1043810-g011.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>Conclusion</title>
<p>In summary, Eu-CP-Ara micro/nanospheres with luminescence properties, good bioactivity, good biocompatibility and good dispersibility in water have been successfully prepared for our study. The results have demonstrated that the luminescence properties wavelength of Eu-CP-Ara is emission centering at about 619&#xa0;nm. Meanwhile, Eu-CP-Ara has stronge inhibitory effect on the activity of A549 cells and lower cytotoxicity to normal liver cells (L02). Based on these results, Eu-CP-Ara can be used as a potential anticancer drug. The combination of this luminescence properties, Eu-CP-Ara may be an effective strategy for the tracking cytarabine against tumours and might impart better accurate treatment effect and therapeutic efficiency. The use of micro/nanoparticle-based formulations and cell pharmacodynamic experiment might provide a novel topical therapeutic approach. As for their antitumor activity and luminescence properties, wide bioapplications may be found.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6">
<title>Author contributions</title>
<p>ZZ, HS, WG, QG, MC, and YJ performed the experiments. XY, HL, and YJ analyzed the data. ZZ, HL, and YJ designed the project. ZZ and YJ wrote the paper.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>This work was supported by the National Natural Science Foundation of China (81760787), Technology Innovation Guidance Program of Jiangxi Province (National Science and Technology Award Backup Program Cultivation Program, 20192AEI91002), Collaborative Innovation of Modern Science and Technology and Industrial Development of Jiangxi National Traditional Medicine (Gan Jiao Gao Zi, (2013) No. 109), Jiangxi middle-aged and young backbone Talents Project of traditional Chinese medicine (Gan TCM Ke Jiao Zi (2021) No. 2) and Jiangxi University of Chinese Medicine Science and Technology Innovation Team Development Program (CXTD22005 and CXTD22007).</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abanades Lazaro</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Haddad</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rodrigo-Munoz</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Orellana-Tavra</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Del Pozo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Fairen-Jimenez</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Mechanistic investigation into the selective anticancer cytotoxicity and immune system response of surface-functionalized, dichloroacetate-loaded, UiO-66 nanoparticles</article-title>. <source>ACS Appl. Mat. Interfaces</source> <volume>10</volume>, <fpage>5255</fpage>&#x2013;<lpage>5268</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.7b17756</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alfaifi</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Elbehairi</surname>
<given-names>S. E. I.</given-names>
</name>
<name>
<surname>Hafez</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Elshaarawy</surname>
<given-names>R. F. M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Spectroscopic exploration of binding of new imidazolium-based palladium(II) saldach complexes with CT-DNA as anticancer agents against HER2/neu overexpression</article-title>. <source>J. Mol. Struct.</source> <volume>1191</volume>, <fpage>118</fpage>&#x2013;<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1016/j.molstruc.2019.04.119</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alinaghi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Karami</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shahpiri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nasab</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Momtazi-Borojeni</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Abdollahi</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A Pd(II) complex derived from pyridine-2-carbaldehyde oxime ligand: Synthesis, characterization, DNA and BSA interaction studies and <italic>in vitro</italic> anticancer activity</article-title>. <source>J. Mol. Struct.</source> <volume>1219</volume>, <fpage>128479</fpage>. <pub-id pub-id-type="doi">10.1016/j.molstruc.2020.128479</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ameri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Norouzi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sourati</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Azghandi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Novin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Taghizadeh-Hesary</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Randomized trial on acute toxicities of weekly vs three-weekly cisplatin-based chemoradiation in head and neck cancer</article-title>. <source>Cancer Rep.</source> <volume>5</volume>, <fpage>e1425</fpage>. <pub-id pub-id-type="doi">10.1002/cnr2.1425</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arru&#xe9;</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Santoyo-Flores</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pizarro</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zarate</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>P&#xe1;ez-Hern&#xe1;ndez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schott</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The role played by structural and energy parameters of &#x3b2;-Diketones derivatives as antenna ligands in Eu(III) complexes</article-title>. <source>Chem. Phys. Lett.</source> <volume>773</volume>, <fpage>138600</fpage>. <pub-id pub-id-type="doi">10.1016/j.cplett.2021.138600</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cakar</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Tekgunduz</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dal</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Merdin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Basci</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Iskender</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The effect of high-dose cytarabine followed by autologous hematopoietic stem cell transplantation on the outcome of patients with mantle cell lymphoma</article-title>. <source>J. Oncol. Pharm. Pract.</source> <volume>26</volume>, <fpage>273</fpage>&#x2013;<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1177/1078155219841110</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>pH responsible and fluorescent Cy5.5-PEG-g-A-HA/CDDP complex nanoparticles: synthesis, characterization, and application for targeted drug delivery</article-title>. <source>J. Mat. Sci. Mat. Med.</source> <volume>30</volume>, <fpage>58</fpage>. <pub-id pub-id-type="doi">10.1007/s10856-019-6260-8</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eftekhari far</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nasr-Esfahani</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Synthesis, characterization and application of Fe3O4@SiO2@CPTMO@DEA-SO3H nanoparticles supported on bentonite nanoclay as a magnetic catalyst for the synthesis of 1, 4-dihydropyrano[2, 3-c]pyrazoles</article-title>. <source>Appl. Organomet. Chem.</source> <volume>34</volume>, <fpage>e5406</fpage>. <pub-id pub-id-type="doi">10.1002/aoc.5406</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Three coordination polymers based on 5-(1H-tetrazol-5-yl)isophthalic acid: Syntheses, structure, magnetic properties</article-title>. <source>J. Solid State Chem.</source> <volume>264</volume>, <fpage>15</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.jssc.2018.04.036</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Valdivia</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Cepeda</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Medina-O&#x27;donnell</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Oyarzabal</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Parra</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>5-Aminopyridine-2-carboxylic acid as appropriate ligand for constructing coordination polymers with luminescence, slow magnetic relaxation and anti-cancer properties</article-title>. <source>J. Inorg. Biochem.</source> <volume>207</volume>, <fpage>111051</fpage>. <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2020.111051</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. Z.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z. R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Rambeck</surname>
<given-names>W. A.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Effect of dietary rare Earth elements on growth performance and blood parameters of rats</article-title>. <source>J. Anim. Physiol. Anim. Nutr. Berl.</source> <volume>87</volume>, <fpage>229</fpage>&#x2013;<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1046/j.1439-0396.2003.00432.x</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>Y.-C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>F.-H.</given-names>
</name>
<name>
<surname>Kan</surname>
<given-names>W.-Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.-R.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Two novel Co(II)-based coordination polymers with hms and pcu nets: Syntheses, structures and properties</article-title>. <source>Inorg. Chem. Commun.</source> <volume>86</volume>, <fpage>78</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.inoche.2017.09.026</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirsch</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Abermil</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Flandrin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Moatti</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Favale</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia</article-title>. <source>Haematologica</source> <volume>102</volume>, <fpage>1227</fpage>&#x2013;<lpage>1237</lpage>. <pub-id pub-id-type="doi">10.3324/haematol.2016.159681</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Ovarian cancer: Beyond resistance</article-title>. <source>Nature</source> <volume>527</volume>, <fpage>S217</fpage>. <pub-id pub-id-type="doi">10.1038/527S217a</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horniichuk</surname>
<given-names>O. Y.</given-names>
</name>
<name>
<surname>Kariaka</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Smola</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Rusakova</surname>
<given-names>N. V.</given-names>
</name>
<name>
<surname>Trush</surname>
<given-names>V. O.</given-names>
</name>
<name>
<surname>Sliva</surname>
<given-names>T. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Efficient sensitized luminescence of binuclear ln(III) complexes based on a chelating bis-carbacylamidophosphate</article-title>. <source>J. Fluoresc.</source> <volume>31</volume>, <fpage>1029</fpage>&#x2013;<lpage>1039</lpage>. <pub-id pub-id-type="doi">10.1007/s10895-021-02733-0</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ibarra-V&#xe1;zquez</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Alvarado-Rodr&#xed;guez</surname>
<given-names>J. G.</given-names>
</name>
<name>
<surname>Esqueda</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Rangel-Salas</surname>
<given-names>I. I.</given-names>
</name>
<name>
<surname>Serrano</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Synthesis, structural characterization, and activity on the transfer hydrogenation reaction of dimesitylacetonate piano stool organometallic complexes of Ru(II), Rh(III), and Ir(III)</article-title>. <source>J. Mol. Struct.</source> <volume>1191</volume>, <fpage>52</fpage>&#x2013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.molstruc.2019.04.029</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jabbour</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cortes</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Giles</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>O&#x27;Brien</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kantarjian</surname>
<given-names>H. M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Current and emerging treatment options in chronic myeloid leukemia</article-title>. <source>Cancer</source> <volume>109</volume>, <fpage>2171</fpage>&#x2013;<lpage>2181</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.22661</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Yttrium(iii) coordination polymer micro/nanospheres with single ligand and dual ligands</article-title>. <source>RSC Adv.</source> <volume>10</volume>, <fpage>32357</fpage>&#x2013;<lpage>32362</lpage>. <pub-id pub-id-type="doi">10.1039/d0ra05325b</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Obese rats intervened with Rhizoma coptidis revealed differential gene expression and microbiota by serum metabolomics</article-title>. <source>BMC Complement. Med. Ther.</source> <volume>21</volume>, <fpage>208</fpage>. <pub-id pub-id-type="doi">10.1186/s12906-021-03382-3</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kant</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Maji</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Recent advances in the synthesis of piperazine based ligands and metal complexes and their applications</article-title>. <source>Dalton Trans.</source> <volume>50</volume>, <fpage>785</fpage>&#x2013;<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1039/d0dt03569f</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kantarjian</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>X. G.</given-names>
</name>
<name>
<surname>Dmoszynska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wierzbowska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mazur</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia</article-title>. <source>J. Clin. Oncol.</source> <volume>30</volume>, <fpage>2670</fpage>&#x2013;<lpage>2677</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2011.38.9429</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kearns</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zwaan</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Reinhardt</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nysom</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia</article-title>. <source>Br. J. Haematol.</source> <volume>186</volume>, <fpage>e7</fpage>&#x2013;<lpage>e11</lpage>. <pub-id pub-id-type="doi">10.1111/bjh.15847</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khanagwal</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hooda</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>PoonamKhatkar</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Taxak</surname>
<given-names>V. B.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Designing of luminescent complexes of europium(III) ion with hydroxyl ketone and nitrogen donor secondary ligands for improving the luminescence performance and biological actions</article-title>. <source>Inorganica Chim. Acta</source> <volume>525</volume>, <fpage>120463</fpage>. <pub-id pub-id-type="doi">10.1016/j.ica.2021.120463</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leonard</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Woodman</surname>
<given-names>C. B.</given-names>
</name>
<name>
<surname>Kearns</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia</article-title>. <source>PLoS ONE</source> <volume>9</volume>, <fpage>e87475</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0087475</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Luan</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Self-assembling nanoparticles based on cytarabine prodrug for enhanced leukemia treatment</article-title>. <source>J. Mol. Liq.</source> <volume>251</volume>, <fpage>178</fpage>&#x2013;<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1016/j.molliq.2017.12.086</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z. Y.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Crystal structures, antioxidation and DNA binding properties of Eu(III) complexes with Schiff-base ligands derived from 8-hydroxyquinoline-2-carboxyaldehyde and three aroylhydrazines</article-title>. <source>J. Inorg. Biochem.</source> <volume>103</volume>, <fpage>1014</fpage>&#x2013;<lpage>1022</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2009.04.013</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>2D near&#x2010;infrared luminescence ln&#x2013;coordination&#x2010;polymers as an assistor for biomedicine</article-title>. <source>ChemistrySelect</source> <volume>5</volume>, <fpage>10771</fpage>&#x2013;<lpage>10774</lpage>. <pub-id pub-id-type="doi">10.1002/slct.202001050</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Long</surname>
<given-names>B.-F.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>G.-F.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>F.-L.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Homocoupling of arylboronic acids catalyzed by dinuclear copper(I) complexes under mild conditions</article-title>. <source>J. Iran. Chem. Soc.</source> <volume>16</volume>, <fpage>2639</fpage>&#x2013;<lpage>2646</lpage>. <pub-id pub-id-type="doi">10.1007/s13738-019-01728-w</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Cyclometalated iridium(iii) complex nanoparticles for mitochondria-targeted photodynamic therapy</article-title>. <source>Nanoscale</source> <volume>12</volume>, <fpage>14061</fpage>&#x2013;<lpage>14067</lpage>. <pub-id pub-id-type="doi">10.1039/d0nr03398g</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nato</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Miyazaki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Imai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nakano</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kageyama</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ino</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Early central nervous system relapse of monomorphic epitheliotropic intestinal T-cell lymphoma after cord blood transplantation</article-title>. <source>Int. J. Hematol.</source> <volume>114</volume>, <fpage>129</fpage>&#x2013;<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1007/s12185-021-03107-9</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okamura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Washio</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yoshimoto</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tani</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tsukahara</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Exchange transfusion and cytarabine for transient abnormal myelopoiesis in hydrops fetalis</article-title>. <source>Acta Med. Okayama</source> <volume>73</volume>, <fpage>181</fpage>&#x2013;<lpage>188</lpage>. <pub-id pub-id-type="doi">10.18926/AMO/56655</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettinari</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pettinari</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Xhaferai</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Giambastiani</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rossin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bonfili</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Binuclear 3, 3&#x2032;, 5, 5&#x2032;-tetramethyl-1H, H-4, 4&#x2032;-bipyrazole Ruthenium(II) complexes: Synthesis, characterization and biological studies</article-title>. <source>Inorganica Chim. Acta</source> <volume>513</volume>, <fpage>119902</fpage>. <pub-id pub-id-type="doi">10.1016/j.ica.2020.119902</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pola</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pokorna</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vockova</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bohmova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pechar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Karolova</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma</article-title>. <source>Acta Biomater.</source> <volume>119</volume>, <fpage>349</fpage>&#x2013;<lpage>359</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2020.11.014</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Razmara</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Poorsargol</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Ultrasonic-assisted synthesis of supramolecular copper (II) complex a precursor for the preparation of octahedron Cu2O nanoparticles applicable in the adsorption and photodegradation of Rhodamine B</article-title>. <source>Appl. Organomet. Chem.</source> <volume>33</volume>, <fpage>e5084</fpage>. <pub-id pub-id-type="doi">10.1002/aoc.5084</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salgado</surname>
<given-names>O. G. G.</given-names>
</name>
<name>
<surname>Teodoro</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Alvarenga</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>de Carvalho</surname>
<given-names>T. S.</given-names>
</name>
<name>
<surname>Domiciano</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Cerium alleviates drought-induced stress in Phaseolus vulgaris</article-title>. <source>J. Rare Earths</source> <volume>38</volume>, <fpage>324</fpage>&#x2013;<lpage>331</lpage>. <pub-id pub-id-type="doi">10.1016/j.jre.2019.07.014</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwabe</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Gr&#xfc;n</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Voigt</surname>
<given-names>K. D.</given-names>
</name>
<name>
<surname>Flachowsky</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>D&#xe4;nicke</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Effect of rare Earth elements (REE) supplementation to diets on the carry-over into different organs and tissues of fattening bulls</article-title>. <source>Livest. Sci.</source> <volume>143</volume>, <fpage>5</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.livsci.2011.08.010</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Synthesis and anticancer property of three new Ca (II) compounds derived from tetrazole carboxylate ligands</article-title>. <source>Inorganica Chim. Acta</source> <volume>509</volume>, <fpage>119659</fpage>. <pub-id pub-id-type="doi">10.1016/j.ica.2020.119659</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Versatile hyaluronic acid modified AQ4N-Cu(II)-gossypol infinite coordination polymer nanoparticles: Multiple tumor targeting, highly efficient synergistic chemotherapy, and real-time self-monitoring</article-title>. <source>Biomaterials</source> <volume>154</volume>, <fpage>197</fpage>&#x2013;<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.11.001</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Sialic acid-engineered mesoporous polydopamine nanoparticles loaded with SPIO and Fe(3&#x2b;) as a novel theranostic agent for T1/T2 dual-mode MRI-guided combined chemo-photothermal treatment of hepatic cancer</article-title>. <source>Bioact. Mat.</source> <volume>6</volume>, <fpage>1423</fpage>&#x2013;<lpage>1435</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioactmat.2020.10.020</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trusova</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Yudintsev</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Limanskaya</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gorbenko</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Deligeorgiev</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Europium coordination complexes as potential anticancer drugs: Their partitioning and permeation into lipid bilayers as revealed by pyrene fluorescence quenching</article-title>. <source>J. Fluoresc.</source> <volume>23</volume>, <fpage>193</fpage>&#x2013;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1007/s10895-012-1134-1</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Usman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Abul Farah</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>BinSharfan</surname>
<given-names>I. I.</given-names>
</name>
<name>
<surname>Alharbi</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A novel biocompatible formate bridged 1D-Cu(ii) coordination polymer induces apoptosis selectively in human lung adenocarcinoma (A549) cells</article-title>. <source>Dalton Trans.</source> <volume>50</volume>, <fpage>2253</fpage>&#x2013;<lpage>2267</lpage>. <pub-id pub-id-type="doi">10.1039/d0dt03782f</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vorob&#x27;ev</surname>
<given-names>V. N.</given-names>
</name>
<name>
<surname>Sibgatullin</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Sterkhova</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Alexandrov</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Gogolev</surname>
<given-names>Y. V.</given-names>
</name>
<name>
<surname>Timofeeva</surname>
<given-names>O. A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Ytterbium increases transmembrane water transport in Zea mays roots via aquaporin modulation</article-title>. <source>Biometals</source> <volume>32</volume>, <fpage>901</fpage>&#x2013;<lpage>908</lpage>. <pub-id pub-id-type="doi">10.1007/s10534-019-00221-4</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Nanoscale metal-organic frameworks for drug delivery: A conventional platform with new promise</article-title>. <source>J. Mat. Chem. B</source> <volume>6</volume>, <fpage>707</fpage>&#x2013;<lpage>717</lpage>. <pub-id pub-id-type="doi">10.1039/c7tb02970e</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wuttke</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Braig</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Preiss</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zimpel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sicklinger</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bellomo</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>MOF nanoparticles coated by lipid bilayers and their uptake by cancer cells</article-title>. <source>Chem. Commun. (Camb.)</source> <volume>51</volume>, <fpage>15752</fpage>&#x2013;<lpage>15755</lpage>. <pub-id pub-id-type="doi">10.1039/c5cc06767g</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Quickly evaluating the synergistic effects of top anti-cancer drugs by the computer high performance computing power and complex network visualization</article-title>. <source>J. Intell. Fuzzy Syst.</source> <volume>38</volume>, <fpage>277</fpage>&#x2013;<lpage>281</lpage>. <pub-id pub-id-type="doi">10.3233/jifs-179402</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>Z. J.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y. N.</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>Z. M.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>W. P.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Integrating the metpa and ipa to verify the biological function of the potential biomarkers from plasma metabonomics in diabetic rats</article-title>. <source>Acta Medica Mediterr.</source> <volume>35</volume>, <fpage>1627</fpage>&#x2013;<lpage>1631</lpage>. <pub-id pub-id-type="doi">10.19193/0393-6384_2019_3_254</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nie</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qinying</surname>
<given-names>A. I.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Efficacy of Kushen decoction on high-fat-diet-induced hyperlipidemia in rats</article-title>. <source>J. Tradit. Chin. Med.</source> <volume>42</volume>, <fpage>364</fpage>&#x2013;<lpage>371</lpage>. <pub-id pub-id-type="doi">10.19852/j.cnki.jtcm.20220225.002</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia</article-title>. <source>Ann. Hematol.</source> <volume>98</volume>, <fpage>2223</fpage>&#x2013;<lpage>2225</lpage>. <pub-id pub-id-type="doi">10.1007/s00277-019-03674-2</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.-L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>F.-Q.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Two new Eu(III)-Based coordination polymer nanoparticles constructed from the V-shaped carboxylic linkers: Synthesis, crystal structures and anti-oral cancer studies</article-title>. <source>J. Inorg. Organomet. Polym. Mat.</source> <volume>28</volume>, <fpage>2714</fpage>&#x2013;<lpage>2720</lpage>. <pub-id pub-id-type="doi">10.1007/s10904-018-0924-6</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>F. Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Q. J.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Anneal-induced transformation of phase structure, morphology and luminescence of GdPO4:Sm3&#x2b; nanomaterials synthesized by a hydrothermal method</article-title>. <source>Dalton Trans.</source> <volume>46</volume>, <fpage>2948</fpage>&#x2013;<lpage>2956</lpage>. <pub-id pub-id-type="doi">10.1039/c6dt04583a</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>